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Abstract
Background: The expression of the Prospero homeodomain transcription factor (Prox1) in a subset of cardinal venous cells
specifies the lymphatic lineage in mice. Prox1 is also indispensible for the maintenance of lymphatic cell fate, and is
therefore considered a master control gene for lymphangiogenesis in mammals. In zebrafish, there are two prox1
paralogues, the previously described prox1 (also known as prox1a) and the newly identified prox1b.
Principal Findings: To investigate the role of the prox1b gene in zebrafish lymphangiogenesis, we knocked-down prox1b
and found that depletion of prox1b mRNA did not cause lymphatic defects. We also generated two different prox1b mutant
alleles, and maternal-zygotic homozygous mutant embryos were viable and did not show any lymphatic defects.
Furthermore, the expression of prox1b was not restricted to lymphatic vessels during zebrafish development.
Conclusion: We conclude that Prox1b activity is not essential for embryonic lymphatic development in zebrafish.
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Introduction
In vertebrates, in addition to the blood vasculature, the
lymphatic vasculature plays important roles in maintaining an
effective circulation. It is responsible for returning the protein-rich
interstitial lymph fluid to the blood stream. Lymphatic vessels also
contribute to the immune system that protects the body against
infectious agents, and absorb lipids from the intestinal tract.
Furthermore, there are a large number of inherited or acquired
diseases that are associated with lymphatic vessel malfunction and
lymphatic vessels may provide a primary route for the metastatic
spread of certain tumors [1,2,3].
The lymphatic vessels were first described in 1627 by Aselli [4].
In 1902, Sabin proposed the origin of the lymphatic system from
the veins [5]. The recent identification of several transcription
factors, Prox1, Sox18, and CoupTF-II [6,7,8], which are essential
for the specification of lymphatic cell fate, now provides a better
understanding of the molecular mechanism of lymphatic devel-
opment in metazoans.
In mice, the lymphatic system arises from a subset of venous
endothelial cells (ECs) which start to express the homeodomain
gene Prox1 from E9.75. By subsequent polarized budding and
sprouting, Prox1-expressing cells migrate away from the cardinal
vein and give rise to the entire lymphatic system [6,9]. In Prox1
null mice, lymphatic development is arrested, while the
development of the blood vascular system is largely unaffected
[6].
It has been reported that Prox1 plays similar roles in other
vertebrate organisms, such as Xenopus and zebrafish [10,11]. In
zebrafish, the initial process of vasculogenesis leads to the
formation of a primitive circulatory loop by 26 hpf (hours post
fertilization), which consists of the posterior cardinal vein (PCV)
and dorsal aorta (DA). A primary wave of angiogenesis,
emanating from the DA, produces intersegmental arteries
(ISAs), while a secondary wave of venous angiogenesis gives
rise to sprouts that either remodel half of the existing ISAs into
ISVs (intersegmental veins) by 2.5 dpf, or become parachordal
lymphangioblasts (PLs), constituting a precursor pool of
lymphangioblasts formed around 50 hpf at the horizontal
myoseptum [12,13]. At 60 hpf, the PLs start to migrate along
ISAs, and move dorsally or ventrally to form the dorsal
longitudinal lymphatic vessel (DLLV), the thoracic duct (TD)
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used indicator for normal lymphatic development. The prox1b
gene was recently identified in zebrafish and its activity was
claimed to be essential for zebrafish lymphangiogenesis and TD
formation, using a morpholino knock-down approach [15].
Furthermore, prox1b was suggested to provide a molecular
marker for lymphatic endothelial cells. We had performed
similar experiments in the past, with different results. Here, we
show that two mutant alleles of prox1b do not alter lymphatic
development, and that prox1b i sn o tau s e f u lm a r k e rf o r
lymphatic endothelial cells in zebrafish.
Results
Prox1b is expressed in endothelial cells and the cranial
central nervous system
In mice, Prox1 is expressed in a variety of tissues other than
lymphatic endothelial cells, including the lens, the heart, liver,
pancreas, and central nervous system (CNS) [16]. By whole mount
in situ hybridization, we were able to detect prox1b expression in the
lateral plate mesoderm (LPM) and in the CNS of the head at
12 hpf stage (Figure 1 A–C). Since zebrafish endothelial cells
(which provide the inner lining of blood and lymphatic vessels)
originate from the LPM, we intended to follow prox1b over time.
Figure 1. Prox1b is expressed in the endothelial cells and the central nervous system of the head. (A–C) shows prox1b transcript
expression by whole mount in situ hybridization in wild-type embryos, at 12 hpf. Black arrows point to prox1b expression in the head; red arrows
indicate prox1b expression in lateral plate mesoderm. Confocal image (D) shows YFP expression in a prox1b BAC:YFP embryo at 19 hpf stage. (E) and
(F) show YFP expression, enhanced by DAB immunostaining, is detected in prox1b BAC:YFP embryos in migrating angioblasts at 15 hpf. (G–I) shows
prox1b:YFP expression in the head region of a prox1b BAC:YFP, fli1:DsRed embryo. Note overlapping (endothelial cells) and non-overlapping
expression domains. (J) shows prox1b:YFP expression in the trunk vasculature. (K) shows enlarged view of the boxed area in (J). Scale bars represent
50 mm in (K), and 100 mm in other figures.
doi:10.1371/journal.pone.0028934.g001
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expression of prox1b gene in live embryo, we generated a Tol2-
mediated bacterial artificial chromosome (BAC) transgenic line in
zebrafish [17]. The overall morphology of the transgenic embryos
appeared normal and was indistinguishable from wild type
embryos (Figure 1D and J, and Figure 2D and E).
The prox1b BAC:YFP construct was created by inserting the
yellow fluorescence protein (YFP) coding sequences at the position
of the first translated ATG in a prox1b-harboring BAC (CH73-
247L15) through homologous recombination [17]. This BAC
contains approximately a 116-kb long zebrafish genomic contig,
spanning from ,97.7-kb upstream of the prox1b start codon to
,18.6-kb downstream of the start codon, and harbors the entire
prox1b coding sequence. We verified the correct knock-in of YFP in
the prox1b gene based on diagnostic PCR (data not shown) and
performed extensive analyses of the YFP expression in the
prox1b:YFP embryos.
YFP expression in live embryo was not detected via confocal
microscopy until late somitogenesis stages, when it was evident in
the intermediate cell mass (derived from the earlier LPM and
containing the trunk vascular precursors), but not in the head
region (Figure 1D). To amplify the signal, we applied anti-GFP
immunostaining with diaminobenzidin (DAB) solution in fixed
embryos and were able to detect YFP expression in LPM as early
as 15hpf (Figure 1E and F). Using standard in situ hybridization
(ISH), we could confirm that prox1b is expressed, at 24 hpf, in the
caudal vein (Figure S1A–C). As the development of the embryos
proceeded, the expression level of YFP increased and signals also
became apparent in more anterior aspects of the embryos
(Figure 1G–I). At 30 hpf, in the head of prox1b BAC:YFP;
fli1:DsRed double transgenic embryos [13], YFP expression
partially overlapped with the red signals which marked all
endothelial cells (Figure 1G–I). This indicates that the prox1b gene
is expressed in both a subset of endothelial cells and some non-
endothelial aspects of the central nervous system of the head. At
the same stage, we detected bright YFP expression in all trunk
endothelial cells: posterior cardinal vein (PCV), dorsal aorta (DA),
and inter-segmental vessels (ISVs) (Figure 1J). In transgenic
embryos we noted that the YFP signal level in the DA often
appeared brighter than in the PCV (Figure 1K), however, using
ISHs, we routinely observed that mRNA levels were equally high
in the PCV (Figure S1D–F), sometimes even higher in the PCV
than in the DA. Both YFP expression in transgenic embryos
(Figure 2A–C) and ISHs confirm a rather broad expression in the
caudal vein, the PCV and the DA. This dynamic prox1b:YFP
expression in zebrafish ECs is hence different from Prox1
Figure 2. Prox1b does not specifically mark lymphatic aspects of the vasculature. (A–C) shows prox1b:YFP expression in motor neurons and
all endothelial cells of a prox1b BAC:YFP, fli1:DsRed embryo at 48 hpf. White arrows point to parachordal lymphangioblasts. The white open
arrowheads label motor neurons. Note that while there is expression of prox1:YFP in PLs, prox1b is also expressed in other (non-lymphatic) aspects of
the vasculature. (D) and (E) show the fluorescence images of the same 5-day prox1b BAC:YFP, fli1:DsRed embryo. There is no detectable prox1b:YFP
expression in the trunk region of the transgenic embryos (E). (F) and (G) show the enlarged views of the boxed area in (D) and (E). (F) White
arrowheads indicate the TD, which resides between DA and PCV. (G) prox1b:YFP expression cannot be detected in TD. (H) and (J) show weak DAB
immunostaining against YFP expression in the head (H, indicated by the black arrow), but not in the trunk of transgenic embryos (J). (I) and (K) are
DAB staining controls without primary antibody. Scale bars represent 250 mm in (D), and 50 mm in other figures.
doi:10.1371/journal.pone.0028934.g002
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to lymphatics, venous lymphatic precursors and venous valves
[18].
Prox1b expression is not restricted to lymphatic
endothelial cells
In mice, Prox1 is required for both the specification of LEC fate
and the maintenance of LEC cell identity. Prox1 expression is not
detected in the blood endothelial cells (BECs) after E11,5, but
persists in the lymphatic vasculature until and throughout
adulthood [18,19]. We therefore examined the distribution of
zebrafish prox1b:YFP expression and prox1b mRNA expression in
late stage LECs. At 5 dpf, when the thoracic duct and
intersegmental lymphatic vessels have formed, we were not able
to detect any YFP expression in the trunk of prox1b:YFP embryos
(Figure 2D–G and J, K), but observed weak signals in the head
(Figure 2H and I).
prox1b ISH signals in the trunk of embryos at 48 hpf and 72 hpf
had previously been reported [15]. Using a prox1b probe, we
detected only diffuse expression in the trunk at these stages (Figure
S1G–L), which we would normally consider non-specific. To test
the specificity of this staining, we performed ISH for prox1b in cloche
mutant embryos, which are devoid of all ECs (Figure S2A and B)
[20,21]. Since the staining pattern was unaltered in mutants,
compared to wild-type embryos at 48 hpf and 72 hpf (Figure S2C,
D and S1G, H, J, and K), we conclude that prox1b expression in
ECs is no longer detectable by ISH from 48 hpf and after 72 hpf
(Figure S1G–O). Therefore, different from Prox1 expression in
mice, prox1b is not a specific and persistent lineage marker for
LECs in zebrafish.
Knock-down of prox1b does not lead to impaired
lymphatic development
As prox1b expression in the vasculature is not restricted to LECs,
we wondered whether Prox1b is required for lymphatic develop-
ment of zebrafish.
Initially, we used two different antisense morpholinos (splA MO
and splB MO) to knock down prox1b gene activity. Both
morpholinos were designed to target the splice sites of the prox1b
gene (Figure 3A and B). The results of reverse transcription-PCR
(RT-PCR) analysis showed that splA MO inefficiently blocked the
excision of intron 3–4 (367 bp), leaving a substantial amount of
correctly processed transcripts in morpholino injected embryos
(Figure 3A), while injection of splB MO caused a loss of detectable
wild-type prox1b transcripts, leading to the accumulation of non-
spliced prox1b transcripts (retaining of intron2-3 leads to frame shift
after aa494) (Figure 3B). However, ,70% of splA MO injected
embryos developed lymphatic defects: a complete or partial loss of
TD at 5 dpf (Figure 3C). In contrast, we could not detect a similar
phenotype in splB MO injected embryos (Figure 3D–H).
The presence of a TD in splB MO injected embryos indicates
that loss of prox1b still allows for normal lymphatic development.
The phenotypes observed in splA MO injected embryos are likely
to be side-effects due to toxicity, and indeed we have in the past
seen many examples where MO-injection affects TD-formation
(unpublished observation). Since our data are in conflict with
recently published information [15], we decided to generate stable
mutant loss-of-function models, alleviating the need to have to rely
on morpholinos.
Prox1b mutants develop normally
We screened for prox1b mutants from an in-house TILLING
(targeting induced local lesion in genome) library [22] and
identified the prox1b
hu3510 allele (Figure S3A), with a stop mutation
in the homeodomain of the gene. The mutant line was maintained
in the fli1:GFP background, where all endothelial cells are marked
by GFP expression [23,24]. We observed that, at 48 hpf, the
secondary venous sprouts occurred normally and the formation of
PLs was unaffected in homozygous mutant embryos (Figure S3B
and C). Indistinguishable from wild-type embryos, the homozy-
gous mutants developed a completely normal TD at 5 dpf (Figure
S3D–G). Homozygous prox1b
hu3510 mutant embryos were viable,
although the mutation changed a highly conserved amino acid
(W627) into a stop codon, which would be predicted to alter the
function of the Prox1b Homeo-Prospero (HPD) domain by
removing residues that bind the DNA phosphate backbone and
by unmasking the C-terminal nuclear export sequence [25].
In an effort to obtain an additional allele, we received the
prox1b
sa0035 line from the Sanger Centre. This allele harbors a
mutation at amino acid 236. This mutation would predict a
truncated Prox1 protein with the loss of the entire Homeo-
Prospero domain, which is indispensable for Prox1 homologues to
function as transcription factors (Figure 4A). We maintained the
prox1b
sa0035 allele in fli1:GFP and SAGFF27C;UAS:GFP (heterozy-
gous SAGFF27C;UAS:GFP line displays high reporter expression in
lymphatic vasculature) transgenic background [12]. The
prox1b
sa0035 homozygous mutant embryos were also viable and
developed normally (Figure 4B–G). Both the specification and
migration of the lymphatic endothelial cells were unaffected in the
mutants, as the formation of PLs (Figure 4B and C) and TD was
indistinguishable from wild type embryos (Figure 4F and G). The
prox1b
sa0035 homozygous fish are fertile. To exclude the possibility
that maternal prox1b mRNA might rescue a possible homozygous
zygotic phenotype, we crossed prox1b
sa00352/2, SAGFF27-
C;UAS:GFP fish, and generated maternal-zygotic (MZ) prox1b
mutant progeny. These MZ mutant embryos have no visible
defects (Figure 5A and B) and we observed a properly formed
embryonic lymphatic network, including DLLV, ISLVs and TD,
at 5 dpf (Figure 5C and D).
The analysis of two prox1b mutant alleles demonstrates that
prox1b gene activity is not necessary for any known indispensible
functional process during the development of zebrafish. In
combination with the prox1b expression and knock-down analysis,
we conclude that Prox1b activity is not essential for zebrafish
embryonic lymphatic development.
Discussion
It has been recently reported that zebrafish prox1b expression
marks lymphatic endothelial cells, and that knock-down of prox1b
via morpholinos completely abolishes lymphangiogenesis [15]. We
here report that two mutant alleles of prox1b undergo normal
lymphangiogenesis, and that, at least at later stages of develop-
ment, prox1b expression does not mark lymphatic endothelial cells.
In mammals, the activities of the transcription factors Coup-
TFII [8], Sox 18 [7] and Prox1 [6] lead to the specification of a
subpopulation of anterior cardinal vein cells into future lymphatic
endothelial cells (LECs) [6,7,8]. Subsequently, Ccbe1, VEGF-C
and its receptor, VEGFR3, are required for outgrowth of these
prospective LECs. For the latter process, there is excellent genetic
evidence for strong evolutionary conservation between mice and
zebrafish: mutations in Ccbe1 [14,26], VegfC and Vegfr3
[11,27,28,29] are deficient in most aspects of venous sprouting
and consequently lack a thoracic duct. The phenotypic effects of
lacking Coup-TFII, Sox 18 and Prox1 are less well supported in
zebrafish (no mutants for either of these genes have been reported)
and have started to be elucidated only recently. Knock-down of
prox1b Mutants Develop Lymphatic Vasculature
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28934Figure 3. Morpholino-mediated knock-down of prox1b does not cause lymphatic phenotypes. (A) and (B) show schematics of the prox1b
genomic locus with the red bars indicating target sites of the respective splice morpholinos. The numbered black arrows show the position of the
primers used in RT-PCRs for examining the splicing of prox1b transcripts. (A) RT-PCR to detect splicing of prox1b in un-injected (UIC) and splA MO
injected embryos. The expression of elongation factor 1-alpha (ef1a) gene represents the loading control. Primer pair F1 and R1 amplifies wild-type
transcript band (558 bp) and incorrectly spliced transcripts (925 bp), which fail to excise the intron3-4 (367 bp). Primer pair F1 and R2 amplifies wild-
type transcript (247 bp) and non-spliced transcripts (614 bp), which retain intron3-4. (B) RT-PCR to detect splicing of prox1b in un-injected and
embryos injected with splB MO. Primer pair F2 and R2 amplifies wild-type transcripts (529 bp), which are missing in splB MO injected embryos. Primer
pair F2 and R3 amplifies non-spliced transcripts (729 bp), which preferentially accumulated in morphant embryos. (C) Histograms showing the
percentage of fli1:GFP embryos with different lengths of TD (10 s,TD,20 s means the partial TD covers the length of 10 to 20 somites in the trunk).
Up to 70% of splA MO injected embryos displayed complete or partial loss of TD, even though splA MO seems not to affect prox1b splicing efficiently.
Embryos were scored at 5 dpf. (D) Histograms showing the percentage of fli1:GFP embryos with intact or defective TD, and all the scorable embryos
(their overall morphology was all right and they had normal blood circulation and did not develop edema at 5 dpf) developed complete TD after
injection with splB MO. (E) and (F) show the full images of 5-day UIC (E) and splB MO injected embryos (F). (G) and (H) show enlarged views of the
boxed areas in (E) and (F). The white arrowheads indicate the presence of TD in both control embryos (G) and morphants (H). Scale bars represent
250 mm in (E), and 25 mm in (G).
doi:10.1371/journal.pone.0028934.g003
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been independently reported to have no phenotype by three
groups [31,32,33]. Since the effect of Sox18 in mice is context-
dependent, this might not be completely surprising [7]. Finally, in
the case of Prox1, a recent study reported a requirement for prox1b
in embryonic lymphatic formation [15].
Our conclusion that Prox1b activity is not essential for
lymphatic development, is contradictory to a previous report
[15]. In previous work, the function of Prox1b was studied by
using a morpholino knock-down approach. Only a single
morpholino covering the first translated ATG was employed in
the study, however, the authors demonstrated rescue of the
morphant phenotype by injection of mRNA. Here, we show
analysis with a splice (splB) morpholino, which we demonstrate to
deplete nearly all wild-type prox1b transcripts, while not causing
any lymphatic defects. The presence of a TD in splB MO injected
embryos indicates that loss of prox1b still allows normal lymphatic
development. Although we cannot explain the published mRNA
rescue experiments, all our results indicate that the lymphatic
defects observed in ATG and splA MO injected embryos are most
likely not due to loss of Prox1b function. Of note, the prox1b
morpholino used in the previous study causes severe edema at
4 dpf. We take this as evidence of considerable toxicity of the
morpholino, as from previous studies [14,29], it is clear that lack of
lymphatic tissue does not cause edema at this early stage. The
toxicity might be the cause for the reduction of lyve-1 expression in
morphants.
Furthermore, we analyzed two mutant alleles that provide an
additional method to study prox1b function. Homozygous mutants
for both alleles, and even maternal-zygotic mutants, develop
normally without visible defects. Prox1b shares high homology
with Drosophila Prospero (Pros) in the homeodomain and
prospero domain (PD). Both proteins contain a nuclear export
signal (NES) in the homeodomain. Based on a previous study [25],
a physiological signal induces Pros to adopt a closed conformation
so that the PD shields the NES and Pros enters the nucleus and is
prepared for DNA binding. If the NES masking is turned off or
blocked, Pros adopts an open structure that exposes NES and exits
the nucleus [25]. The prox1b
hu3510 allele harbors a non-sense
mutation, which deletes the C-terminal part of the PD, which
contains a highly conserved DNA binding residue Lys629, and is
also essential to physically cover the NES in the homeodomain, so
the predicted truncated protein is unlikely to adopt the closed
conformation and be kept in the nucleus for proper DNA binding.
The other allele, prox1b
sa0035, is predicted to be truncated after
the coil-coil domain, and does not contain the homeodomain and
Figure 4. The lymphatic development of homozygous
prox1b
sa0035 mutants appears normal. (A) Schematic representation
of the Prox1b protein, with the position of the prox1b
sa0035 allele
indicated. The homeodomain region (HD) is shown in red, the Prospero
domain (PD) in green. The predicted stop mutation occurs at C236 in
prox1b
sa0035. (B) and (C) show vascular structures in the trunk region of
wild-type (wt, B) and homozygous prox1b
sa0035 mutant embryos (C) in
fli1:GFP background. The white arrows indicate PLs. (D) and (E) show
whole embryo lateral view images of 5-day wt (D) and homozygous
prox1b
sa0035 mutant embryos (E). (F) and (G) show enlarged views of the
boxed areas in (D) and (E). The white arrowheads indicate the presence
of TD in both control (F) and homozygous prox1b
sa0035 embryos (G).
Scale bars represent 50 mm in (B), 250 mm in (D) and 25 mm in (F).
doi:10.1371/journal.pone.0028934.g004
Figure 5. The lymphatic development of maternal-zygotic
prox1b
sa0035 mutant is unaltered. (A) and (B) show whole embryo
lateral view images of 5-day wt (A) and MZ prox1b
sa0035 mutant (B) in a
SAGFF27C;UAS:GFP background. Perfused blood vessels were labeled by
angiography (in red). (C) and (D) show enlarged views of the boxed
areas in (A) and (B). The entire lymphatic network in the trunk of
zebrafish, which is composed of the GFP-expressing lymphatic vessels-
DLLV, ISLV and TD (marked by white arrowheads), is properly formed in
wt (C) and MZ prox1b
sa0035 mutant embryos (D). Scale bars represent
250 mm in (A), and 25 mm in (C).
doi:10.1371/journal.pone.0028934.g005
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certainly lack wild-type activity of Prox1b, and that at least the
prox1b
sa0035 allele represents a loss-of-function situation. Although
we cannot exclude the possibility of a compensatory transcrip-
tional mechanism involving other prox homologues, or of a
complex transcript processing event to remove these coding
mutations, we have not been able to detect any evidence to
support either of these hypotheses. Injections of prox1a morpho-
linos into prox1b mutants at lower dose did not affect TD formation
(data not shown; low doses of morpholinos had to be used since
prox1a morpholinos are toxic). Based on two mutant alleles and the
splB morpholino, we conclude that the activity of Prox1b is
dispensable during zebrafish development.
In zebrafish, LECs arise from the PCV sprouts that do not
connect to ISAs, and approximately half of the venous spouts fall
into this class. These sprouts migrate to the horizontal midline and
become lymphatic precursors, dubbed PLs [14]. It is unclear at
present whether the lymphatic fate of these venous sprouts is
determined before they emanate from the PCV, or whether they
get specified during their migration from PCV to horizontal
myoseptum. If prox1b was a specific LEC lineage marker
comparable to mammalian Prox1, its early expression around
30 hpf, would be expected to be found in a polarized manner,
present in a salt-and-pepper pattern in the dorsal side of the PCV
or restricted to half of the venous spouts that constitute future PLs.
At later stages, prox1b expression should only be observed in
lymphatic endothelial cells (PLs and TD, DLLV, and ISLVs) but
not blood endothelial cells. This is not what we observe: rather,
prox1b expression is detected in all endothelial cells and is not
enriched at the dorsal side of the PCV around 30 hpf. After that
point in time, prox1b expression in endothelial cells becomes
increasingly weaker. Although a few PLs seem to have brighter
expression at 48 hpf, prox1b expression is never exclusively
observed in LECs, instead it is also present in BECs (Figure 2A–
C). Furthermore, prox1b expression is not maintained in LECs, and
eventually it completely disappears from the zebrafish trunk
vasculature, and at 5 days there was no expression detectable in
the TD or any other trunk endothelial tissue (Figure 2G, J and
S1M–O). Based on our results, prox1b is not a LEC-specific marker
in zebrafish.
In mice, the expression of Coup-TFII in the blood vasculature is
restricted to veins and it inhibits Notch activity and blocks an
arterial signaling cascade in venous endothelial cells (VECs) [34].
At embryonic day E9, Sox18 expression becomes apparent in a
subset of cells in the anterior cardinal vein and induces Prox1
expression in these cells around E9.75 [7,35], in synergy with
Coup-TFII [8]. The direct interaction between Coup-TFII and
Prox1 is also necessary for the maintenance of Prox1 expression
during early stages of LEC specification and differentiation
[8,36,37]. In zebrafish, the lymphatic cells also arise from VECs,
the secondary sprouts of the PCV [12,13]. However, the
molecular mechanisms that initiate lymphatic specification remain
unclear and might be different from mammals. Recent work from
Aranguren et al., indicates a conserved role of Coup-TFII for
venous and lymphatic development in zebrafish [30]. Knockdown
of Sox18 alone failed to reveal any phenotype [32,33], and the
simultaneous knockdown of sox18 and sox7 severely affected the
arteriovenous identity and led to dramatic fusion between the
major axial vessels [31,32]. So far, there is no clear evidence to
show that SoxF proteins have a role in zebrafish lymphatic
development; however, in mice the function of Sox18 in early
aspects of lymphangiogenesis is also context dependent [7]. It
remains possible that a homeodomain transcription factor,
perhaps a Prox homologue, functions directly downstream of
Coup-TFII to switch on the lymphatic lineage in zebrafish. Since
we demonstrate here that Prox1b is not required for normal
lymphatic development, Prox1a becomes the most likely candi-
date. It was previously reported that the morpholinos targeting
zebrafish prox1a gene usually led to severely delayed or impaired
growth at early stages and eventually caused massive malforma-
tions before a lymphatic phenotype could reasonably be scored
[27]. Therefore, a yet to be identified prox1a mutant would be
required to shed further light onto the molecular pathway that
initiates the lymphatic fate in zebrafish.
Methods
Ethics statement
All zebrafish strains were maintained under standard husbandry
conditions at the Hubrecht Institute, and animal experiments were
approved by the Animal Experimentation Committee (DEC) of
the Royal Netherlands Academy of Arts and Sciences. Permit
number for this study is: 80101.
Morpholinos
All morpholinos were obtained from GeneTools. Prox1b splA
MO (59-CACAGCGATTGAACTGTGTAGCGAG-39) was de-
signed to target the intron3-4/exon4 boundary, while prox1b splB
MO (59-GATAAAAGGATATTGAACCTGCAGC-39) was de-
signed to target the exon2/intron2-3 boundary. Both of the
morpholinos were injected at a concentration of 5 ng/embryo. All
morpholinos and primers were designed according to the prox1b
sequence in GenBank/EMBL database under the accession
number FJ544314.
RT-PCR
Total RNA (1 mg) from wildtype and morpholino injected
embryos was reverse transcribed by using M-MLV Reverse
Transcriptase and random hexamers (Promega). PCR followed by







In situ hybridization was performed as previously described [38].
Prox1b probe was synthesized by in vitro transcription from the
HindIII-digested full length cDNA in pBSK, using T7 RNA
polymerase (Promega).
Embryos were subjected to ISH and paraffin sections (6 mm)
were counter-stained with neutral red.
Microangiography
We performed microangiography as described [27]. Embryos
were anesthetized in 0.015% MS-222 at 5 dpf and were
embedded in 0.5% low melting point agarose. A small bulb of
tetramethylrhodamine (TAMRA; Molecular Probes, 2,000,000
MW, 10 mg/ml) was administered by cardiac injection using a
conventional microinjection setup. Only embryos exhibiting
TAMRA throughout the cardiovascular system immediately after
the injection were further analyzed [27].
Microscopy
Embryos were mounted in 0.5% low melting point agarose in a
culture dish with a cover slip replacing the bottom. Imaging was
prox1b Mutants Develop Lymphatic Vasculature
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objective with digital zoom.
Diaminobenzidine (DAB) histochemistry
DAB staining was performed using VECTASTAIN ABC kit
(VECTOR) and DAB tablet (SIGMA). The expression of YFP was
detected by using rabbit polyclonal anti-GFP (1:500, Torrey Pines
Biolabs, Acris TP401) as primary antibody and polyclonal swine




hu3510 allele was identified from an ENU mutagenesis library
in Hubrecht Institute by Tilling. The prox1b
sa0035 allele was
ordered from Zebrafish Mutation Resource of Sanger Institute.



















t22499 allele has been previously described [32].
Generation of transgenic line
Generation of transgenic lines with bacterial artificial chromo-
some (BAC) was described previously [17]. For the prox1b
BAC:YFP transgenic line, a citrine-neomycin cassette was recom-
bined by using Red/ET Recombination Technology (Gene
Bridges), into the bacterial artificial chromosome (BAC) clones
CH73-247L15 using homology arm tagged PCR primers. DNA
was injected into one cell-stage embryos at a concentration of
500 pg/embryo. A transgenic carrier adult was selected by
screening for fluorescent progeny.
Supporting Information
Figure S1 Prox1b transcript expression in zebrafish. (A–
O) shows prox1b expression analyzed by in situ hybridization in
whole mount embryos (A, D, E, G, H, J, K, M and N) and
transverse sections (B, C, F, I, L, and O), at different stages: 24 hpf
(A–C), 32 hpf (D–F), 48 hpf (G–I), 72 hpf (J–L) and 5 dpf (M–O).
(E), (H), (K) and (N) individually show the enlarged views of the
boxed area in (D), (G), (J) and (M). The blue and red bars in (A)
represent the positions of the sections in (B) and (C). prox1b
expression is prominent in the caudal vein of embryos at 24 hpf
(C) and in both the DA and PCV at 32 hpf stage, shown by (E)
and (F). (G–O) However, there is no signal in the blood and
lymphatic endothelial cells of older embryos at 48 hpf, 72 hpf and
5 dpf. The black arrows point to the dorsal aorta; the blue arrows
point to the posterior cardinal vein or caudal vein; and the red
arrows point to thoracic duct. The black and blue arrow heads
point to the prox1b expression in the DA and PCV separately. NT:
neural tube; NC: notochord. Scale bars represent 200 mm in (A),
(D), (G), (J), (M); 50 mm in (E), (H), (K) and (N); and 20 mm in (B),
(C), (F), (I), (L) and (O).
(TIF)
Figure S2 Prox1b expression in cloche mutant. (A–D)
shows prox1b expression in cloche mutants and siblings. The red and
blue arrows point to prox1b expression in the DA and PCV of a
sibling embryo separately (A), while this prox1b expression is absent
in cloche mutant (B). The black arrows point to signals in the ventral
region of the trunk (C) and along the somite boundaries of
homozygous cloche mutants (D). (E) The inset shows an enlarged
view of the boxed area in (D). The staining indicated by black
arrows in C, D and E is either non-endothelial or non-specific
because cloche mutant embryos lack endothelial cells. Given the
diffuse nature of the staining, the black arrow indicated signal is
probably a non-specific artifact of over-staining. Scale bars
represent 100 mm in (A), and 50 mm in (E).
(TIF)
Figure S3 The lymphatic development of homozygous
prox1b
hu3510 mutant is normal. (A) Schematic representation
of the Prox1b protein, with the position of the prox1b
hu3510 allele
indicated. The homeodomain region is shown in red, the Prospero
domain in green. The predicted stop mutation occurs at W627 in
prox1b
hu3510 and multiple sequence alignment shows the conserva-
tion of zebrafish W627 in the Prospero domain of Prox proteins.
(B) and (C) show the vascular structures in the trunk region of wt
(B) and homozygous prox1b
hu3510 mutant embryos (C) in fli1:GFP
background. The white arrows indicate PLs. (D) and (E) show the
full images of 5-day wt (D) and homozygous prox1b
hu3510 mutant
embryos (E). (F) and (G) show enlarged views of the boxed areas in
(D) and (E). The white arrowheads indicate the presence of TD in
both control (F) and homozygous prox1b
hu3510 embryos (G). Scale
bars represent 50 mm in (B), 250 mm in (D) and 25 mm in (F).
(TIF)
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